Psoriasis and the Life Cycle of Persistent Life Effects

Garshick, Marisa Kardos; Kimball, Alexa B.

doi:10.1016/j.det.2014.09.003

Cited by 25 publications

(25 citation statements)

References 140 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…found that QoL (DLQI score) was more impaired in younger patients, as well as in those with a shorter duration of the disease . The extent of the impact on QoL may be attributed to the fact that these patients are affected by a lifelong skin condition associated with long‐term outcomes that go beyond the physical symptoms, and generally compromise the patient's psychosocial, behavioral and emotional well‐being . Bhatti et al .…”

Section: Discussionmentioning

confidence: 99%

Effect of a family history of psoriasis and age on comorbidities and quality of life in patients with moderate to severe psoriasis: Results from the ARIZONA study

López-Estebaranz

Sánchez‐Carazo

Sulleiro³

2015

The Journal of Dermatology

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory skin disease whose clinical characteristics vary from patient to patient. We aimed to analyze how comorbidities and quality of life (QoL, as per the Dermatology Life Quality Index [DLQI]) may be affected by a family history of psoriasis and by age. The ARIZONA study was a multicenter, cross-sectional study in 1022 adult patients diagnosed with moderate to severe psoriasis at least 6 months prior to inclusion. The severity of psoriasis and the proportion of patients with comorbidities were not affected by the presence of a family history. The regression analysis revealed that the presence of a family history of psoriasis was associated with the effect on the patient's QoL (P = 0.002), regardless of disease severity. The mean DLQI total score varied significantly across age groups (5.1 ± 5.3 for the 18-30-year group, 5.7 ± 6.5 for the 31-60-year group and 3.8 ± 5.1 for the >60-year group; P = 0.001). In conclusion, the presence of a family history of psoriasis appears to disrupt QoL in patients with moderate to severe psoriasis, but it hardly affected the prevalence of comorbid conditions. The effect of age on QoL was particularly noticeable in younger patients, highlighting its negative impact. As expected, older patients appeared to be burdened with a higher number of comorbidities than their younger counterparts.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of a family history of psoriasis and age on comorbidities and quality of life in patients with moderate to severe psoriasis: Results from the ARIZONA study

López-Estebaranz

Sánchez‐Carazo

Sulleiro³

2015

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…Common treatments for psoriasis include topical, systemic, phototherapy, combination, and herbal therapy treatments that inhibit excessive keratinocyte proliferation 3. Despite the fact multiple psoriasis therapies are available, no cure has been developed to date, and the relapsing–remitting nature of psoriasis adversely effects patient quality of life 4 5…”

Section: Introductionmentioning

confidence: 99%

Calcipotriol Inhibits Proliferation of Human Keratinocytes by Downregulating Stat1 and Stat3 Signaling

Liang

Lin²,

Zhang

et al. 2017

Journal of Investigative Medicine

View full text Add to dashboard Cite

Psoriasis is an autoimmune disease, which is characterized by aberrantly high levels of inflammation, but the underlying pathogenic mechanisms are still not fully understood. Signal transducer and activator of transcription 1 (STAT1) and STAT3, and the downstream proteins suppressor of cytokine signaling 1 (SOCS1) and SOCS3, have been implicated in psoriasis disease progression. Calcipotriol, a synthetic derivative of vitamin D, has been used clinically to treat psoriasis, but the mechanism of action that underlies the beneficial effects of calcipotriol is still being explored. The objective of this study was to determine whether STAT1 and STAT3 signaling is involved in calcipotriol treatment. Using an in vitro immortal human keratinocyte cell line, HaCaT cells, as a psoriasis model, we examined the molecular signaling induced by calcipotriol treatment. We found that calcipotriol treatment or silencing of either STAT1 or STAT3 inhibited proliferation of HaCaT cells. Calcipotriol downregulated the expression of STAT1 and STAT3 at the messenger RNA (mRNA) and protein levels. The levels of phosphorylated STAT1 and STAT3 were also decreased, suggesting calcipotriol treatment inhibited STAT1 and STAT3 activation. Calcipotriol-mediated STAT inhibition was further substantiated by the downregulation of SOCS1 and SOCS3 at the mRNA and protein expression levels. Taken together, our results suggest a novel molecular mechanism for calcipotriol-mediated treatment effects in psoriasis.

show abstract

“…Studies often use a general pediatric HRQL measure, PedsQL 4.0, or a dermatology-specific measure adapted from an adult questionnaire. Only one psoriasis-specific measure-described as a linear increase throughout childhood or as a peak of onset in the 16-to 22-year-olds [1,5] .…”

Section: Introductionmentioning

confidence: 99%

Systematic Review of Health-Related Quality of Life in Adolescents with Psoriasis

et al. 2016

View full text Add to dashboard Cite

Background: Many cases of psoriasis begin in adolescence. The affected adolescents face the combined physical and psychosocial challenges of their disease-free peers with the added complexity of a visible disease. Objective: To review the impact of psoriasis on the health-related quality of life (HRQL) in adolescents as compared to their peers with other chronic diseases and to determine the best tools to measure HRQL in this population. Methods: A systematic literature review was completed using PubMed. Results: 256 publications were screened for inclusion, 37 were relevant to objectives and included in the systematic review. Most studies are pediatric psoriasis studies with an adolescent subgroup, very few are dedicated to solely addressing HRQL in adolescents with psoriasis. Adolescents with psoriasis face both the challenges similar to an adult psoriasis population in addition to the complexities inherent to healthy adolescents. Studies often use a general pediatric HRQL measure, PedsQL 4.0, or a dermatology-specific measure adapted from an adult questionnaire. Only one psoriasis-specific measurement tool exists, and it is specifically for scalp psoriasis. Conclusion: Both dermatologists and primary care physicians should treat the visible cutaneous lesions and disease comorbidities and address the psychosocial impact of psoriasis in their adolescent patients. Use of both a general and dermatology-specific HRQL questionnaire may allow physicians to better identify the impact of the disease and recognize improvement or impairment over time.

show abstract

Psoriasis and the Life Cycle of Persistent Life Effects

Cited by 25 publications

References 140 publications

Effect of a family history of psoriasis and age on comorbidities and quality of life in patients with moderate to severe psoriasis: Results from the ARIZONA study

Effect of a family history of psoriasis and age on comorbidities and quality of life in patients with moderate to severe psoriasis: Results from the ARIZONA study

Calcipotriol Inhibits Proliferation of Human Keratinocytes by Downregulating Stat1 and Stat3 Signaling

Systematic Review of Health-Related Quality of Life in Adolescents with Psoriasis

Contact Info

Product

Resources

About